Lebrikizumab

Drug Profile

Lebrikizumab

Alternative Names: MILR1444A; MILR1444Ab; RG-3637; RO-5490255; TNX-650

Latest Information Update: 10 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Tanox
  • Developer Chugai Pharmaceutical; Comprehensive Clinical Research Network; Genentech; Roche; Tanox
  • Class Anti-inflammatories; Antiasthmatics; Monoclonal antibodies
  • Mechanism of Action Interleukin 13 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Atopic dermatitis; Idiopathic pulmonary fibrosis
  • Discontinued Asthma; Chronic obstructive pulmonary disease; Hodgkin's disease

Most Recent Events

  • 08 Aug 2017 Dermira enters into a worldwide licensing agreement with Roche and Genentech to develop and commercialise lebrikizumab in Atopic dermatitis
  • 08 Aug 2017 Dermira plans a dose-ranging phase IIb study to optimise the dose of lebrikizumab for the design of a phase III programme in moderate-to-severe Atopic dermatitis (In adults) in the first quarter of 2018
  • 27 Apr 2017 Discontinued - Phase-II for Chronic obstructive pulmonary disease (Adjunctive treatment) in USA, Bulgaria, Canada, Denmark, Hungary, Poland, Russia, Argentina, Argentina, Mexico (SC) because it did not meet the primary endpoint of a phase II trial (Roche pipeline, April 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top